Excision BioTherapeutics, a company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by viruses, has secured exclusive licenses from UC Berkeley for their newly discovered CRISPR gene editors.

They are the first company to secure licenses to further explore these gene editors as they relate to infectious diseases, including HSV, HBV, HTLV-1, in order to explore possible treatments and/or cures. The licenses also give Excision BioTherapeutics the right to sub-license these editors to others, such as pharmaceutical companies, providing them with new research alternatives to develop medicines or treatments.

“Advancements of this magnitude are exactly what makes ARTIS Ventures so proud to be backing exceptional companies in the biotech space such as Excision BioTherapeutics,” said Stuart Peterson, president of ARTIS Ventures. “These new editors add even greater potential and we look forward to seeing how they leverage them to improve lives.”